AU5789800A - Methods for manipulating the avian genome - Google Patents
Methods for manipulating the avian genome Download PDFInfo
- Publication number
- AU5789800A AU5789800A AU57898/00A AU5789800A AU5789800A AU 5789800 A AU5789800 A AU 5789800A AU 57898/00 A AU57898/00 A AU 57898/00A AU 5789800 A AU5789800 A AU 5789800A AU 5789800 A AU5789800 A AU 5789800A
- Authority
- AU
- Australia
- Prior art keywords
- nucleic acid
- polypeptide
- egg
- avian
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims description 50
- 241000271566 Aves Species 0.000 title claims description 40
- 150000007523 nucleic acids Chemical class 0.000 claims description 61
- 108020004707 nucleic acids Proteins 0.000 claims description 51
- 102000039446 nucleic acids Human genes 0.000 claims description 51
- 241000287828 Gallus gallus Species 0.000 claims description 39
- 230000009261 transgenic effect Effects 0.000 claims description 39
- 108700019146 Transgenes Proteins 0.000 claims description 38
- 235000013330 chicken meat Nutrition 0.000 claims description 33
- 210000002298 blastodisc Anatomy 0.000 claims description 19
- 229920001184 polypeptide Polymers 0.000 claims description 19
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 19
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 19
- 230000001105 regulatory effect Effects 0.000 claims description 18
- 108090001061 Insulin Proteins 0.000 claims description 15
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 15
- 102000004877 Insulin Human genes 0.000 claims description 14
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 14
- 239000012634 fragment Substances 0.000 claims description 12
- 230000017448 oviposition Effects 0.000 claims description 10
- 108010014251 Muramidase Proteins 0.000 claims description 9
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims description 9
- 241001465754 Metazoa Species 0.000 claims description 8
- 238000001727 in vivo Methods 0.000 claims description 8
- 108060001064 Calcitonin Proteins 0.000 claims description 7
- 229940125396 insulin Drugs 0.000 claims description 7
- 239000011159 matrix material Substances 0.000 claims description 7
- 102000055006 Calcitonin Human genes 0.000 claims description 6
- 108010051696 Growth Hormone Proteins 0.000 claims description 6
- 108010071390 Serum Albumin Proteins 0.000 claims description 6
- 102000007562 Serum Albumin Human genes 0.000 claims description 6
- 241000286209 Phasianidae Species 0.000 claims description 5
- 241000287531 Psittacidae Species 0.000 claims description 4
- 238000011534 incubation Methods 0.000 claims description 4
- 239000011435 rock Substances 0.000 claims description 4
- 108090000565 Capsid Proteins Proteins 0.000 claims description 3
- 108700029229 Transcriptional Regulatory Elements Proteins 0.000 claims description 3
- 241000272525 Anas platyrhynchos Species 0.000 claims description 2
- 241000272814 Anser sp. Species 0.000 claims description 2
- 241000726096 Aratinga Species 0.000 claims description 2
- 241000721631 Nymphicus hollandicus Species 0.000 claims description 2
- 241000220010 Rhode Species 0.000 claims description 2
- 241000272534 Struthio camelus Species 0.000 claims description 2
- 239000000122 growth hormone Substances 0.000 claims description 2
- 102000018997 Growth Hormone Human genes 0.000 claims 3
- 235000013601 eggs Nutrition 0.000 description 58
- 210000004027 cell Anatomy 0.000 description 51
- 108020004414 DNA Proteins 0.000 description 31
- 230000014509 gene expression Effects 0.000 description 28
- 108090000623 proteins and genes Proteins 0.000 description 25
- 238000013518 transcription Methods 0.000 description 25
- 230000035897 transcription Effects 0.000 description 25
- 210000001172 blastoderm Anatomy 0.000 description 24
- 239000012528 membrane Substances 0.000 description 15
- 108010000912 Egg Proteins Proteins 0.000 description 13
- 102000002322 Egg Proteins Human genes 0.000 description 13
- 238000001890 transfection Methods 0.000 description 13
- 238000011161 development Methods 0.000 description 12
- 230000018109 developmental process Effects 0.000 description 12
- 238000012986 modification Methods 0.000 description 12
- 230000004048 modification Effects 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 12
- 108010063045 Lactoferrin Proteins 0.000 description 11
- 238000004519 manufacturing process Methods 0.000 description 11
- 239000002773 nucleotide Substances 0.000 description 11
- 125000003729 nucleotide group Chemical group 0.000 description 11
- 102000010445 Lactoferrin Human genes 0.000 description 10
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 10
- 229940078795 lactoferrin Drugs 0.000 description 10
- 235000021242 lactoferrin Nutrition 0.000 description 10
- 239000013598 vector Substances 0.000 description 10
- 210000004681 ovum Anatomy 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 210000003278 egg shell Anatomy 0.000 description 8
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 7
- 101000798114 Homo sapiens Lactotransferrin Proteins 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 6
- 108010058846 Ovalbumin Proteins 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 230000032823 cell division Effects 0.000 description 5
- 210000002969 egg yolk Anatomy 0.000 description 5
- 239000003623 enhancer Substances 0.000 description 5
- 238000001476 gene delivery Methods 0.000 description 5
- 210000004602 germ cell Anatomy 0.000 description 5
- 102000050459 human LTF Human genes 0.000 description 5
- 230000001850 reproductive effect Effects 0.000 description 5
- 210000001550 testis Anatomy 0.000 description 5
- 230000002103 transcriptional effect Effects 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 108091026890 Coding region Proteins 0.000 description 4
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 238000010353 genetic engineering Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 229940092253 ovalbumin Drugs 0.000 description 4
- 108020005065 3' Flanking Region Proteins 0.000 description 3
- 101000751233 Halobacterium salinarum (strain ATCC 700922 / JCM 11081 / NRC-1) 50S ribosomal protein L21e Proteins 0.000 description 3
- 102000016943 Muramidase Human genes 0.000 description 3
- 238000010222 PCR analysis Methods 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 238000004520 electroporation Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 210000000994 inner shell membrane Anatomy 0.000 description 3
- 229960000274 lysozyme Drugs 0.000 description 3
- 239000004325 lysozyme Substances 0.000 description 3
- 235000010335 lysozyme Nutrition 0.000 description 3
- 238000000520 microinjection Methods 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 238000003752 polymerase chain reaction Methods 0.000 description 3
- 230000003362 replicative effect Effects 0.000 description 3
- 230000001177 retroviral effect Effects 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 108010026206 Conalbumin Proteins 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 101000609762 Gallus gallus Ovalbumin Proteins 0.000 description 2
- 108091006905 Human Serum Albumin Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 238000011887 Necropsy Methods 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 108010005991 Pork Regular Insulin Proteins 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 108700026226 TATA Box Proteins 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 210000003837 chick embryo Anatomy 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000013020 embryo development Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 239000004017 serum-free culture medium Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- PIEPQKCYPFFYMG-UHFFFAOYSA-N tris acetate Chemical compound CC(O)=O.OCC(N)(CO)CO PIEPQKCYPFFYMG-UHFFFAOYSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 241000272517 Anseriformes Species 0.000 description 1
- 206010068051 Chimerism Diseases 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 102100031780 Endonuclease Human genes 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 101001035782 Gallus gallus Hemoglobin subunit beta Proteins 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 101000741445 Homo sapiens Calcitonin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 108091093105 Nuclear DNA Proteins 0.000 description 1
- 108010064983 Ovomucin Proteins 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 102100038803 Somatotropin Human genes 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 241000271567 Struthioniformes Species 0.000 description 1
- 101710195626 Transcriptional activator protein Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 210000004712 air sac Anatomy 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000009402 cross-breeding Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000005553 drilling Methods 0.000 description 1
- 230000008143 early embryonic development Effects 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 229940045644 human calcitonin Drugs 0.000 description 1
- 239000012212 insulator Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 230000010311 mammalian development Effects 0.000 description 1
- 210000004997 mammalian reproductive system Anatomy 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 238000003571 reporter gene assay Methods 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 210000005000 reproductive tract Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000000996 thick albumen Anatomy 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000002689 xenotransplantation Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/02—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from eggs
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/30—Bird
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/01—Animal expressing industrially exogenous proteins
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/02—Animal zootechnically ameliorated
- A01K2267/025—Animal producing cells or organs for transplantation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/46—Vector systems having a special element relevant for transcription elements influencing chromatin structure, e.g. scaffold/matrix attachment region, methylation free island
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
- C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
- C12N2830/90—Vector systems having a special element relevant for transcription from vertebrates avian
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Environmental Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Plant Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
WO IU/753UU PCT/USUU/4UU59 METHODS FOR MANIPULATING THE AVIAN GENOME BACKGROUND OF THE INVENTION The invention relates to transgenic avian animals. The ability to create transgenic animals form different species has had great impact on both biomedical research and the biotechnology industry. Transgenic technology has been applied to both laboratory and domestic species for the study of human disease (see, for example. Synder, B.W., et al., Mol. Reprod, and Develop. 40:419-428 (1995)), develop improved agricultural livestock (see, for example, Ebert, K.M. et al., Animal Biotechnology 1:145-159 (1990)), production of pharmaceuticals in milk (see, for review article, Ebert, K.M. and J.P. Selgrath, "Changes in Domestic Livestock through Genetic Engineering" in Applications in Mammalian Development. Cold Spring Harbor Laboratory Press, 1991)), and xenotransplantation (see, for example, Osman, N., et al., Proc. Natl. Acad. Sci USA 94:14677 14682 (1997)). However, the basic technique of microinjection used to create many of these transgenic animals is inefficient, costly, and not easily applicable to all species such as the chicken (see, for example, Love, J., et al.. BioTechnology 12:60-63 (1994)). SUMMARY OF THE INVENTION The invention features methods of manipulating genomic DNA in avian species and to generate transgenic avian animals. A method for introducing a nucleic acid molecule into the genome of an avian species is carried out by contacting in vivo a blastodermal cell of a fertilized hard shelled egg with the nucleic acid molecule. Preferably, the nucleic acid molecule is not associated with a viral coat protein, e.g., the nucleic acid is not delivered in a viral particle. The nucleic acid molecule is introduced directly into the germinal disc of the egg. To avoid disrupting the germinal disc (or blastoderm) or dispersing the blastodermal cells, the nucleic acid is delivered in a volume that is less than the volume of the germinal disc (approximately 100 microliters or less). For example, the volume is greater than 1 microliter and less than 0.5 milliliters and introduction of the nucleic acid does not rupture the area opaca (membrane or sheath surrounding the germinal disc or blastoderm). In preferred embodiments, the nucleic acid is delivered in a volume of 5-100 microliters, more preferably 40-60 microliters, and most preferably, 10-20 microliters. To target blastodermal cells, the nucleic acid is delivered directly into the blastoderm or germinal disc and not to an area adjacent to or below the blastoderm. The thick albumen around the germinal disc is not -1removed before, during, or after the delivery process. The nucleic acid is delivered by passing a needle or microinjection pipet directly through the shell and underlying membrane. Little or no air is introduced into the egg, and the hole in the membrane left by the pipet or needle is small and self-sealing. Accordingly, the method does not require deposition of an aqueous liquid over the opening of the egg to minimize the inadvertent introduction of air into the egg and does not require sealing the opening of the egg after nucleic acid delivery. Optionally, the blastodermal cell is exposed to an electrical current in vivo, e.g., by applying an electrical current across the egg. The method is useful to introduce a nucleic acid such as DNA into the genome of any avian species such as a chicken, an ostrich, an emu, a turkeys, a duck, a goose, a quail a parrot, a parakeet, a cockatoo, or a cockatiel to produce therapeutic proteins or to make an avian model for a non-avian, e.g., human, disease state. For example, the method is used to deliver DNA to blastodermal cells in a fertilized egg of any breed of chicken or any hybrid breed of chicken. Chicken breeds include White Leghorn, White Plymouth Rock, Barred Plymouth Rock, Rhode Island Red, New Hampshire and Dark Cornish. Nucleic acid delivery is timed to optimize uptake of the nucleic acid by blastodermal (totipotent) cells and minimize (or eliminate) uptake by cells which have begun to differentiate into various tissue types. Thus, a blastodermal cell in a fertilized egg is contacted with nucleic acid during developmental stage X of the egg. Delivery takes place at a time after oviposition but before incubation of the egg (at which time cell division and cell differentiation takes place). The nucleic acid encodes a polypeptide or antisense molecule. For example, the nucleic acid contains a sequence encoding an antibody or fragment thereof. The term antibody encompasses an intact tetrameric antibody (e.g., a monoclonal antibody) as well as an immunologically active antibody fragment, e.g., a Fab or (Fab) 2 fragment, an engineered single chain F,. molecule, a chimeric molecule (e.g., an antibody which contains the binding specificity of one antibody, e.g., of murine origin, and the remaining portions of another antibody, e.g., of human origin. Preferably, the antibody or fragment thereof is of human origin. Other polypeptides include an insulin polypeptide (such as a human or porcine insulin polypeptide), a growth hormone polypeptide, a calcitonin polypeptide, or a serum albumin polypeptide. For example, the transgenic nucleic acid encodes a porcine single chain insulin polypeptide. -2- To direct transcription of the transgenic nucleic acid in blastodermal cells of an egg, the nucleic acid construct contains an egg-specific transcriptional regulatory element. Transcriptional regulatory sequence is a generic term used throughout the specification to refer to DNA sequences, such as initiation signals, enhancers, and promoters, which induce or 5 control transcription of protein coding sequences to which they are operably linked. Transcription of the recombinant gene or transgene is under the control of a promoter sequence as well as other transcriptional regulatory sequences. For example, an ovalbumin promoter sequence is used to direct expression of a transgene and a regulatory sequences derived from a chicken lysozyme gene is used to direct equal or equivalent expression of both chains of a 0 transgenic tetrameric antibody molecule. By "promoter" is meant a minimal DNA sequence sufficient to direct transcription. Promoters may be constitutive or inducible, and may be coupled to other regulatory sequences or "elements" which render promoter-dependent gene expression cell-type specific, tissue-specific or inducible by external signals or agents; such elements may be located in the 5' or 3' region of the native gene, or within an intron. 5 A transgene expression construct contains one or more of the following elements: a chicken lysozyme or ovalbumin promoter, a chicken lysozyme enhancer, and a matrix attachment region of a chicken lysozyme gene. The matrix attachment region (U.S. Patent No. 5, 731,178, hereby incorporated by reference) preferably includes a region of the chicken lysozyme gene spanning from position -11.7 to -8.8 or from position +5.3 to +9.0. One or 0 both sequences are connected to the heavy and/or light chain of a tetrameric antibody to provide equal or equivalent expression of the two antibody subunits. Preferably, the region from -11.7 to -8.8 and/or +5.3 to +9.0 of the chicken lysozyme gene is attached to the 5' and/or 3' end of a construct with a heavy and light chain antibody coding region each under the control of its own promoter. The invention includes a transgene expression cassette in 5 which the heavy and light chain coding regions of an antibody are ligated together, each under the direction of its own promoter operably linked to a matrix attachment region. By "operably linked" is meant that a coding sequence and a regulatory sequence(s) are connected in such a way as to permit gene expression when the appropriate molecules (e.g., transcriptional activator proteins) are bound to the regulatory sequence(s). 0 The invention also encompasses transgenic avian animals. The term "transgenic avian animal" refers to a member of an avian species (e.g., a chicken) that contains a transferred nucleic acid sequence, including a transferred protein-encoding and/or regulatory sequence, -3- WU UUf/bUU PC'T/ULJUU/4UUS 9 such that the transferred sequence is integrated into a host chromosome. As a result of such transfer and integration, the transferred sequence may be transmitted through germ cells to the offspring of a transgenic chicken. Thus, transgenic chickens are created by introducing by a method of transfer, new nucleic acid sequences into germ cells. A transgenic avian animal is any bird in which one or more, and preferably all of the cells of the animal, includes a transgene. The transgene is introduced into the cell, directly or indirectly by introduction into a precursor of the cell, e.g., a totipotent blastodermal cell of an avian egg, by way of deliberate genetic manipulation. The term genetic manipulation does not include classical cross-breeding, or in vitro fertilization, but rather is directed to the introduction of a recombinant DNA molecule into a blastodermal cell of an avian egg. This molecule may be integrated within a chromosome, or it may be extrachromosomally replicating DNA. Transgenic avians which include one or more transgenes encoding one or more polypeptides are within the scope of this invention. For example, a double or triple transgenic bird, which includes two or three transgenes can be produced. A transgenic avian animal contains a nucleic acid sequence encoding a non-avian antibody polypeptide, e.g., a human antibody, in its genome. Other transgenic avian animals include those in which the genome has been engineered to contain a nucleic acid sequence encoding a non-avian insulin polypeptide such as a human or porcine insulin polypeptide or one which contains a nucleic acid encoding a calcitonin polypeptide, a growth hormone polypeptide, or a serum albumin polypeptide. Preferably, the polypeptides are of human origin. The transgenic avian animals express the transgenic nucleic acid, and the cells of the transgenic animal produce the transgenic polypeptides. Accordingly, the invention encompasses an isolated avian cell, e.g., an avian blastodermal cell, which contains a transgene encoding an antibody, an insulin, a growth hormone, a serum albumin, or a calcitonin polypeptide. The term "isolated" used in reference to a cell means that the cell is substantially free of other cell types or compositions with which it naturally occurs in a tissue of an animal. The nucleic acids described herein are isolated. An isolated nucleic acid, e.g., an isolated gene, or a fragment thereof, to be transferred into a blastodermal cell of an egg is isolated by any of several methods well known to the art. For example, the nucleic acid molecules are recombinant and/or have been purified from the sequences which flank it in a naturally occurring state, i.e., a DNA has been removed from the sequences which are normally adjacent to the fragment, e.g., the sequences adjacent to the fragment in the genome -4- WU UU/iii33UU 'CTI/U SU/4UU59 in which it naturally occurs. Thus, an isolated nucleic acid molecule is produced synthetically, or by treating mRNA derived from the transcription of the gene with a reverse transcriptase so as to produce a cDNA, or by the direct isolation of the nucleic acid from cells, bacterial clones, or from other sources. The invention includes sequences which hybridize under stringent conditions, with all or part of the sequence reported in a reference sequence and retains a biological function of the reference nucleic acid. For example, the nucleic acid may contain one or more sequence modifications in relation to a reference sequence. Such modifications may be obtained by mutation, deletion and/or addition of one or more nucleotides compared to the reference sequence. Modifications are introduced to alter the activity of the regulatory sequence, e.g., to improve promoter activity, to suppress a transcription inhibiting region, to make a constitutive promoter regulatable or vice versa. Modification are also made to introduce a restriction site facilitating subsequent cloning steps, or to eliminate the sequences which are not essential to the transcriptional activity. Preferably, a modified sequence is at least 70% (more preferably at least 80%, more preferably at least 90%, more preferably at least 95%, more preferably at least 99%) identical to a reference sequence. In the case of a transcriptional regulatory element, the modifications do not substantially alter the transcription promoter function associated with the reference sequence (or a naturally-occurring lactoferrin promoter sequence). For example, promoter modifications are engineered to avoid the site of initiation of transcription and the TATA box. Modified transcriptional regulatory sequences such as enhancers retain at least 50%, preferably at least 75%, preferably at least 95%, and most preferably 100% of the enhancer activity of the reference sequence. Alternatively, the modified sequence directs a level of transcription that is greater than that of the reference sequence. For example, a modified enhancer directs at least 110% of the level of transcription associated with the reference enhancer sequence. Nucleotide and amino acid comparisons are carried out using the Lasergene software package (DNASTAR, Inc., Madison, WI). The MegAlign module used was the Clustal V method (Higgins et al., 1989, CABIOS 5(2):151-153). The parameter used were gap penalty 10, gap length penalty 10. Alternatively, the nucleic acids described herein hybridize at high stringency to a strand of DNA having the reference sequence, or the complement thereof and have transcription regulatory activity. Hybridization is carried out using standard techniques, such -5as those described in Ausubel et al. (Current Protocols in Molecular Biology, John Wiley & Sons, 1989). "High stringency" refers to nucleic acid hybridization and wash conditions characterized by high temperature and low salt concentration, i.e, hybridization at 42 degrees C, and in 50% formamide; a first wash at 65 degrees C, 2X SSC, and 1% SDS; followed by a second wash at 65 degrees C and 0.1% x SSC. Lower stringency conditions suitable for detecting DNA sequences having about 50% sequence identity to a reference gene or sequence are detected by, for example, hybridization at 42 degrees C in the absence of formamide; a first wash at 42 degrees C, in 6X SSC, and 1% SDS; and a second wash at 50 degrees C, in 6X SSC, and 1% SDS. Other features and advantages of the invention will be apparent form the description and the drawings and from the claims. BRIEF DESCRIPTION OF THE DRAWINGS Fig. 1 is a diagram of a fertilized hen's egg. Fig. 2 is a diagram of a transgene expression cassette. DETAILED DESCRIPTION OF THE INVENTION The avian reproductive system is distinct from mammalian reproductive systems in that the female can store sperm and fertilize a single ovum at a time. The new fertilized ovum is large, fragile, and filled with yolk as it enters the reproductive track. Early embryonic development occurs in the oviduct as the egg is formed around the ovum. As the ovum travels down the reproductive tract, it is surrounded by a protective layer of white albumen followed by an inner membrane and hardened shell before being laid (Fig. 1). At the time of oviposition, the ovum has matured from a single cell into a blastoderm (also known as the germinal disc) composed of 40-60,000 cells and development arrests until the hen has laid enough eggs and beings to roost. In the blastoderm state, all cells are totipotent and equally 5 capable of contributing to the germ line of the developing chick. Oviposition is the time at which the egg is laid. In the chicken, oviposition occurs at stage X (a freshly laid egg; about 20 hours of uterine age). The time at which a nucleic acid is introduced into the blastoderm or germinal disc is after oviposition but before incubation of the egg, i.e., before the first cell division after the egg is incubated. To effectively target 0 blastodermal cells, DNA is therefore introduced into the blastoderm of an egg which has been incubated for 6 hours or less. Early stages of development of the egg are indicated by roman numerals, whereas stage of development of an embryonic chick are indicated by arabic -6- WU UU/75J3UU PCI'L/UhU/4UU59 numerals. For example, stage X refers to a stage of development that occurs at about 20 hours uterine age and is characterized by oviposition, whereas stage 10 refers to a stage of embryonic chick development (characterized by tissue differentiation). No tissue differentiation has occurred in stage X of development. Accordingly, genetic manipulation occurs before differentiation of blastodermal cells into embryonic tissue. The germinal disc is distinguished from the germinal crescent region in that the germinal disc contains undifferentiated blastodermal cells (at stage X or before), whereas the germinal crescent region appears in the early stages of chick embryo development (i.e., stages 3-5 or 9-11 of chick embryo development). The cells of the blastoderm are genetically manipulated both in vitro or in vivo using gene delivery techniques and then used to produce transgenic or chimeric chickens by allowing development in the egg, transferring to a recipient unfertilized egg, or transferring to the testes of a sterile rooster for development into spermatogonia. The optimum time for transfection is between oviposition and several hours of activation of the egg in order to reduce the number of target cells for transfection. Nucleic acid delivery and production of transgenic animals The blastoderm is accessed by cutting or drilling a small hole in the egg shell (sitting upright) with a scapel or drill and gently peeling back the inner membrane to expose the white albumen. The blastoderm automatically orients to the top of the yolk and is visualized under light. For the production of chimeric or transgenic chickens, the cells of the blastoderm are transfected in vivo by infusing DNA directly into the blastoderm using a syringe and small gauge needle. The DNA is naked or complexed with lipids or other suitable compounds to facility DNA uptake (e.g., DEAE-dextran). If the DNA is naked, the transfection efficiency is increased by passing an electrical current across the blastoderm or whole egg with a device such as a human heart defibrillator. If a current is passed across the whole egg, two additional holes are made in the egg shell to expose the inner membrane to the current since the shell will not conduct electricity. Alternatively, the blastoderm is removed from the egg and pooled with the cells from several eggs using a small pipet. In vitro, DNA uptake by blastodermal cells is facillitated by such techniques as electroporation, DEAE-dextran treatment, calcium phosphate treatment, or lipofection. Following transfection, the cells are transferred into the germinal disc of an unfertilized egg for development of a transgenic chick or into the testes of a sterile rooster to -7induce development in spermatogonia and sperm for breeding. Chicks produced are tested for the presence of the transgene according to known methods, e.g, by the polymerase chain reaction or southern blot analysis. The overall efficiency of the nucleic acid delivery procedure depends on the method and timing of gene delivery. Transfection efficiency is optionally increase by methods such as 1) subjecting the blastoderm or cells derived from the blastoderm to several rounds of transfection. 2) adding a selectable marker such as but not limited to an antibiotic gene to the DNA vector and infusing the antibiotic into the yolk or testes following transfection or cell transfer. The method is applicable to all birds including, but not limited to, chickens, turkeys ostriches, and geese. The critical factor for the efficiency of gene delivery is the timing of egg activation in relation to transfection. The optimal time to transfect the cells is after oviposition and within six hours of activation (post-incubation) so that the cells have started to grow but have not undergone a cell division. The following are examples of the preferred embodiments of the inventions and specifically related to the production of transgenic chickens for the production of pharmaceuticals in eggs. The structure or composition of the transgene has little or no effect on the transfection efficiency of the methods described. Preferred transgene constructs include those carrying the ovalbumin promoter operatively linked to the human serum albumin gene, human insulin gene, native or modified porcine insulin gene, calcitonin gene, or and gene encoding and antibody variable region. The invention includes transgenic chickens carrying any of the above mentioned genes directed to expression in the egg. Example 1: In vivo nucleic acid delivery Fertilized eggs are laid and collected (day 1). The eggs are shipped at room temperature (unincubated) (day 2). Optionally, the eggs are allowed to site upright for at least 24 hours (day 3) at room termperature (unincubated) prior to manipulation for nucleic acid delivery. A fertilized hen's egg was collected and placed in a humidified incubator for between 1 and 6 hours to activate the egg. A hole was cut in the egg shell using a dremel and the inner membrane was folded back. The egg was placed on a light to visualize the germinal disc which was infused with a lipid/DNA complex. The inner membrane was folded into place and the egg sealed with parafilm. The egg was placed back into the incubator and allowed to -8- WO UU/753UU CT/UISUU/4UUS9 develop to term. A blood sample or inner membrane sample was taken from the resulting chick and tested for the presence of the transgene by the polymerase chain reaction with transgene specific primers. A mosaic or chimeric chick is bred to a rooster to produce fully transgenic offspring. Example 2: In vitro DNA delivery of blastodermal cells and transfer of transfected eggs to an unfertilized egg Ten to twenty fertilized hen's eggs are placed in a humidified incubator for between 1 and 6 hours to activate cell division. A hole is cut in the egg shell using a dremel and the inner membrane folded back in order to visualize the blastoderm. The blastoderms are removed from the eggs with a large bore pipet tip and combine in a conical tube. The yolk is removed by washing with phosphate buffered saline, and the blastoderms collected by centrifugation. The cells are dispersed by treatment with collagenase or gentle pipetting and collect by centrifugation. The cells are resuspended in serum free media containing 1-5 g of transgene and allowed to sit at room temperature in an electroporation cuvette. The cells are gently 5 resuspended and electroporated at 300-500V and 250-960uF. Following transfection, the cells are transferred into the germinal disc of an unfertilized egg by cutting a hole in the egg shell, folding back the inner membrane, and infusing the cells into the disc with a syringe and large gauge needle. The egg is sealed and incubated in a humidified incubator to allow development. A blood sample is taken from the resulting chick and tested for the presence of D the transgene by the polymerase chain reaction with transgene specific primers using standard methods. Example 3: In vitro DNA delivery of blastodermal cells and transfer of transfected egs to rooster testes Ten to twenty fertilized hen's eggs are placed in a humidified incubator for between 1 5 and 6 hours to activate cell division. A hole is cut in the egg shell using a dremel and the inner membrane folded back in order to visualize the blastoderm. The blastoderms are removed from the eggs with a large bore pipet tip and combined in a conical tube. The yolk is removed by washing with phosphate buffered saline, and the blastoderms collected by centrifugation. The cells are suspended in serum free media containing 1-5 g of transgene and allowed to sit D at room temperature in an electroporation cuvette. The cells are gently resuspended and electroporated at 300-500V and 250-96uF. Following transfection, the cells are transferred -9into the testes of a sterilized rooster to induce development into spermatogonia. The rooster is monitored for breeding and sperm collected to test for the presence of the transgene. Example 4: Vector Construction To target expression of insulin to the magnum cells of an egg laying hen, a genomic 5 sequence encoding human insulin was operatively linked to a promoter which directs transcription of a nucleic acid to which it is operably linked in avian eggs. For example, the promoter is a human lactoferrin promoter. The construction of a human lactoferrin expression cassette is described in patent application USSN 09/490,801, the contents of which are hereby incorporated by reference. 10 For example, transcription regulatory elements are derived from a milk specific promoter, e.g., a mammalian lactoferrin gene promoter. The expression cassette contains a promoter region derived from the human lactoferrin gene operably linked to a heterologous sequence. A heterologous sequence is one that does not encode a lactoferrin polypeptide. The promoter region includes at least 20 nucleotides of the nucleotide sequence of SEQ ID NO:1. 15 For example, the promoter region contains nucleotides 1-154 of SEQ ID NO: 1 or 2. Table 1: Human Lactoferrin promoter region 1 CTGGATCCTCAAGGAACAAGTAGACCTGGCCGCGGGGAGT 41 GGGGAGGGAAGGGGTGTCTATTGGGCAACAGGGCGGCAAA 20 81 GCCCTGAATAAAGGGGCGCAGGGCAGGCGCAAGTGCAGAG 121 CCTTCGTTTGCCAAGTCGCCTCGAGACCGCAGACATGAAA 161 GCATGTCTCCGCGGAAAA (SEQ ID NO:1) BamHI1 restriction site GGATCC (nucleotides 5-8) and XhoI site (nucleotides 140 25 145) are italicized. These restriction sites may be altered, e.g., replaced with other restriction sites or with nucleotides that do not represent restriction enzyme recognition sites. Table 2: Human Lactoferrin promoter region 1 CTNNNNNNTCAAGGAACAAGTAGACCTGGCCGCGGGGAGT 30 41 GGGGAGGGAAGGGGTGTCTATTGGGCAACAGGGCGGCAAA 81 GCCCTGAATAAAGGGGCGCAGGGCAGGCGCAAGTGCAGAG 121 CCTTCGTTTGCCAAGTCGCNNNNNNACCGCAGACATGAAA GCATGTCTCCGCGGAAAA (SEQ ID NO:2) 35 Optionally, the lactoferrin-derived promoter regions described above are linked to the nucleotide sequence of SEQ ID NO:3 (GENBANK T M accession no. S52659). -10- Table 3: 5' Region of human lactoferrin gene 1 cgaggatcat ggctcactgc caccttcatc tcccaggctc aaatggtcct cccactttag 61 cctcccaagt agctgggacc ataggcatac accaccatgc tgggctaatt tttgtatttt 121 ttgtagagat gggggtttcc ctatgaagcc caggctagtc ttgaactcct gggctcaagc 181 gatcctccca tcttggcctc ccaaagtgct gggattacag gcatgagcca ctgtgccctg 241 cctagttact cttgggctaa gttcacatcc atacacacag gatattcttt ctgaggcccc 301 caatgtgtcc cacaggcacc atgctgtatg tgacactccc ctagagatgg atgtttagtt 361 tgcttccaac tgattaatgg catgcagtgg tgcctggaaa catttgtacc tggggtgctg 421 tgtgtcatgg gaatgtattt acgagatgta ttcttagaag cagtattcta gcttttgaat 481 tttaaaatct gacatttatg gcgattgtta aaatgaggtt accatttcct attgaatact 541 atcaacacca aaaaagaaga aggaggagat ggagaaaaaa aagacaaaaa aaaaaaaagt 601 ggtagggcat cttagccata gggcatcttt ctcattggca aataagaaca tggaaccagc 661 cttgggtggt ggccattccc ctctgaggtc cctgtctgtt ttctgggagc tgtattgtgg 721 gtctcagcag ggcagggaga taccccatgg gcagcttgcc tgagactctg ggcagcctct 781 cttttctctg tcagctgtcc ctaggctgct gctgggggtg gtcgggtcat cttttcaact 841 ctcagctcac tgctgagcca aggtgaaagc aaacccacct gccctaactg gctcctaggc 901 accttcaagg tcatctgctg aagaagatag cagtctcaca ggtcaaggcg atcttcaagt 961 aaagaccctc tgctctgtgt cctgccctct agaaggcact gagaccagag ctgggacagg 1021 gctcaggggg ctgcgactcc taggggcttg cagacctagt gggagagaaa gaacatcgca 1081 gcagccaggc agaaccagga caggtgaggt gcaggctggc tttcctctcg cagcgcggtg 1141 tggagtcctg tcctgcctca gggcttttcg gagcctggat cctcaaggaa caagtagacc 1201 tggccgcggg gagtggggag ggaaggggtg tctattgggc aacagggcgg ggcaaagccc 1261 tgaataaagg ggcgcagggc aggcgcaagt ggcagagcct tcgtttgcca agtcgcctcc 1321 agaccgcaga catgaaactt gtcttcctcg tcctgctgtt cctcggggcc ctcggtgagt 1381 gcaggtgcct gggggcgcga gccgcctgat gggcgtctcc tgcgccctgt ctgctaggcg 1441 ctttggtccc tgtgtccggt tggctgggcg cggggtctct gcgccccgcg gtcccagcgc 1501 ctacagccgg gaggcggccc ggacgcgggg ccagtctctt tcccacatgg ggaggaacag 1561 gagctgggct cctcaagccg gatcggggca cgcctagctc tgctcagagc ttctcaaaag 1621 gcctcccagg cccctgtccc tttgtgtccc gcctaaggat ttggtcccca ttgtattgtg 1681 acatgcgttt tacctgggag gaaagtgagg ctcagagagg gtgagcgact agctcaagga 1741 ccctagtcca gatcctagct cctgcgagga ctgtgagacc ccagcaagac cgagccttta 1801 tgagacttag tttcttcact taaagaaacg gcctaaccat gggtccacag ggttgtgagg 1861 aggagatggg gcattcgcac accttccgtg gcagagggtt gtggaggggt gcggtgctcc 1921 tgatggaacc ctgtgtcaga gggtttgaga gggaaatgtc agccaaacag aaggaaggag 1981 cagaaggaag gaaacaattg tcagttccat aaccaaagta atttctcggg tgctcagagg 2041 gcactcccca gcgctgcaca ttagtgacct aaatgcgtga gtgcgg (SEQ ID NO: 3) The nucleic acid molecules and constructs described herein are isolated. By "isolated" is meant a nucleic acid molecule that is free of the genes which, in the naturally-occurring genome of the organism, flank the sequence of interest. The term therefore includes, for example, a recombinant DNA which is incorporated into a vector; into an autonomously replicating plasmid or virus; or into the genomic DNA of a procaryote or eucaryote; or which exists as a separate molecule (e.g., a cDNA or a genomic or cDNA fragment produced by PCR or restriction endonuclease digestion) independent of other sequences. It also includes a -11recombinant DNA which is part of a hybrid gene encoding additional polypeptide sequence. The term excludes large segments of genomic DNA, e.g., such as those present in cosmid clones, which contain a given DNA sequence flanked by one or more other genes which naturally flank it in a naturally-occurring genome. Lactoferrin-derived transcription regulatory sequences, are attached to a nominal promoter (e.g., the nominal lactoferrrin promoter or a heterologous promoter) which in turn is operably linked to a sequence to be transcribed. The heterologous sequence to be transcribed is a polypeptide-encoding sequence or antisense sequence. When incorporated into a transgenic mammal such as a member of an avian species, the regulatory sequences of the invention operably linked to a polypeptide-encoding sequence direct production of the encoded polypeptide in avian tissues. The lactoferrin-derived regulatory sequence, e.g., promoter sequence is positioned 5' to a heterologous nucleic acid sequence, e.g., a transgene, in a transcription unit. Portions of the lactoferrin-derived promoter region are tested for their ability to allow tissue-specific and elevated expression of a transgene using assays known in the art, e.g., standard reporter gene assays using luciferase, beta-galactosidase, or expression of an antibiotic resistance gene as a detectable marker for transcription. All or part of one of the nucleotide sequences specified in a reference sequence, e.g., SEQ ID NO: 1 or 2, its complementary strand or a variant thereof may be used in to direct transcription of a heterologous nucleic acid sequence such as a transgene in a transgenic mammal. A nucleic acid fragment is a portion of at least 20 continuous nucleotides identical to a portion of length equivalent to one of the reference nucleotide sequences or to its complement. Other promoters which direct transcription in eggs of an avian animal are known in the art, e.g., the chicken ovalbumin promoter (GENBANKT" J00895 or M24999) and the chicken lysozyme promoter (GENBANK T M J00886 or V00429). An expression vector is constructed using a chicken ovalbumin promoter for expression of cloned sequences (Gannon et al., Organisation and sequences at the 5'end of a cloned complete ovalbumin gene. Nature 278:428434; Lai et al., The ovalbumin gene: Structural sequence in native chicken DNA are not contiguous. Proc. Natl. Acad. Sci. USA 75(5): 2205-2209; and Kaye et al., EMBO J. 3:1137-1144). Other regulatory elements which direct transcription of transgenes include a nuclear DNA attachment element which mediates elevated and position-independent gene activity (Stief, A., et al., Nature 341:343-345) and an attachment element for stimulation of -12eucaryotic expression systems (Sippel et al., U.S. Patent No. 5,731,178). Other promoters useful to direct transcription of transgenes in eggs include the conalbumin, ovomucoid, and ovotransferrin promoters known in the art. For expression in blood or liver tissues, a promoter derived from the chicken beta globin gene is used (Foley et al., Proc. Natl Acad Sci USA 91:7252-7256). Protein or polypeptide products to be expressed by the transgene include human insulin
(GENBANK
T M V00565), human calcitonin (GENBANK T M X15943; Broad et al., Nucl. Acids Res. 17:6999-7011), human serum albumin (GENBANK T M M12523, J04457), and a porcine single chain insulin. The nucleic acid sequence of the porcine single chain insulin sequence are shown below in Tables 4 and 5. Table 4: Porcine Single Chain Insulin sequence 1 CTCGAGATGAAAAGATTCGTTAACCAACACTTGTGCGGTTCCCACTTGTTGAAGCT TTGTACTTGGTTTGCGGTGAAAGAGGTTTCTTCTACACTCCTAAGGCTGCTAAGGG TATTGTCGAACAATGCTGTACCTCCATCTGCTCCTTGTACCAATTGGAAAACTACT GCAACTAGACTCGAG (SEQ ID NO:4) Table 5: Porcine Single Chain Insulin sequence with lysozvme signal sequence CTCGAGATGAGGTCTTTGCTAATCTTGGTGCTTTGCTTCCTGCCCCTGGCTGC TCTGGGGAAAAGATTCGTTAACCAACACTTGTGCGGTTCCCACTTGTTGAAGCTT TGTACTTGGTTTGCGGTGAAAGAGGTTTCTTCTACACTCCTAAGGCTGCTAAGGGT ATTGTCGAACAATGCTGTACCTCCATCTGCTCCTTGTACCAATTGGAAAACTACTG CAACTAGACTCGAG (SEQ ID NO:5; bold type indicates signal sequence) The invention includes sequences which hybridize under stringent conditions, with all or part of the sequence reported in a reference sequence and retains transcription regulatory function. For example, the nucleic acid may contain one or more sequence modifications in relation to a reference sequence. Such modifications may be obtained by mutation, deletion and/or addition of one or more nucleotides compared to the reference sequence. Modifications are introduced to alter the activity of the regulatory sequence, e.g., to improve promoter activity, to suppress a transcription inhibiting region, to make a constitutive promoter regulatable or vice versa. Modification are also made to introduce a restriction site facilitating subsequent cloning steps, or to eliminate the sequences which are not essential to the transcriptional activity. Preferably, a modified sequence is at least 70% (more preferably at least 80%, more preferably at least 90%, more preferably at least 95%, more preferably at least 99%) identical to a reference sequence. The modifications do not substantially alter the -13vT.." UtJI ,.,auu transcription promoter function associated with the reference sequence (or a naturally occurring lactoferrin promoter sequence). For example, modifications are engineered to avoid the site of initiation of transcription and the TATA box. Example 5: Construction of a lactoferrin expression cassette A lactoferrin expression cassette was constructed using lactoferrin transcription regulatory elements. The cassette contained 3Kb of promoter and 7Kb of 3' flanking sequence with unique SalI and NotI restriction sites at the 5' and 3'ends, respectively. In addition, the vector contained a unique XhoI site for the addition of heterologous coding sequences. The human insulin gene was PCR amplified from human genomic DNA with the primers HINF3 (5'GCCCTCGAGGACAGGCTGCATCAGAA3'; (SEQ ID NO:6))/HINR3 (5'CTCGGTGCTCGAGGCGGCGGGTGT3'; SEQ ID NO7) cloned into the vector pCR2.1 (Invitrogen, Carlsbad,CA) according to the manufacturer's instructions. The gene sequenced using the Amplicycle Sequencing kit (PE Applied Biosystems, Foster City, CA) to confirm that no base mutations had occurred during amplification. The gene was excised from the vector pCR2.1 as and XhoI fragment and cloned into the XhoI site of the human lactoferrin expression cassette. The orientation of the insulin gene was confirmed by restriction analysis and DNA sequencing. The completed vector was designated HL31 and could be excised from the bacterial backbone as a SalI to NotI fragment. Example 6: Preparation of HL31 for Transfection To remove bacterial sequences from the vector HL31, it was digested with SalI and NotI to completion, extracted with phenol/chloroform, chloroform, and fractionated on a 1% Tris Acetate agarose gel. The transgene was excised from the gel and electro-eluted in dialysis tubing containing 1 x Tris-Acetate buffer. The eluted DNA was transferred into an eppendorf tube and precipitated by adding 1/10th volume 3M sodium acetate pH5.2, 2.2 volumes ethanol, and incubating at -20 degrees C for 24 hrs. The DNA was collected by centrifugation at 13,000 x g for 10 minutes and resuspended in distilled sterile water. The concentration of DNA was estimated by Tris-borate gel electrophoresis against a known quantity of lambda HindIII digested standard. The DNA was stored at 4 degrees C. Example 7: Production of Chimeric Transgenic Chickens Developmental stage X chicken eggs from white leghorn chickens were obtained from a commercial vendor (Charles River/SPAFAS, North Franklin, CT). The eggs were allowed -14- WO 00/75300 PCT/US00/40059 to acclimate for 24 hrs at room temperature prior to transfection to allow the germinal disc/blastoderm to orient to the top of the egg. Using a dremel, a 1-2cm circular cut was made in eggshell over the air sac region. Before proceeding, the transgene was prepared for injection at the following concentrations; DNA 5-15 ng/ 1, 10-15% phospholipid (Life Technologies, Grand Island, NY), 50% Dulbecco's Modified Eagles media, and the remaining volume with phosphate buffered saline. The DNA/lipid is allowed to stand at room temperature for a minimum of 15minutes prior to injection into the egg. Just prior to injection, the eggshell was removed to expose the inner shell membrane and allow the visualization of the germinal disc. If the germinal disc could not be visualized a small opening was made in the membrane. Following location of the germinal disc, the DNA/lipid solution was injected directly into the center of the disc. Nucleic acid solutions (construct encoding human insulin) were injected in a volume of 50-100 1 with a 1cc syringe and 27 gauge needle or in a volume of 10-20 1 with a microinjection needle attached to a Hamilton syringe. Table 6 shows data from representative experiments. 228 eggs were injected and 26 chicks were hatched (Table 6) Table 6: Summary of Eg Injection Experiments Experiment Conc. Of DNA Percent # of Eggs # of Chicks (ng/ 1) Phospolipid Injected Hatched 32 15 15 16 3 33 10 15 22 2 34 5 20 22 9 34a 7.5 10 22 2 35 15 10 21 1 36 15 10 21 3 37 10 5 30 4 38 5 10 30 2 39 10 10 30 0 40 10 10 30 0 -15- Chimerism of the hatched chicks was tested by PCR analysis of genomic DNA isolated from the inner shell membrane (post-hatching), or the liver, kidney, and reproductive organs upon necropsy (Table 7). Out of the 3 chicks tested in experiment 32, 2 showed a strong PCR signal in the inner shell membrane sample. Upon maturation, these chicks are bred to confirm germline transmission of the transgene. PCR analysis of necropsy samples (membrane and reproductive organs) taken from 4 chicks derived from experiments 32 & 33 revealed that 1 out of 4 chicks had detectable levels of the transgene its reproductive organs. Table 7 shows results from a representative analysis of tissue expression of human insulin transgene in chimeric chickens produced as described above. Table 7: PCR analysis of Genomic DNA Isolated from Chimeric Chicks Experiment Chick Tissue Sample Status Inner Reproductive Membrane Organ 32 C NEG. Not tested Alive E POS. Not tested Alive M POS. Not tested Alive N NEG. NEG. Dead O POS. NEG. Dead 33 B Not tested Not tested Alive BB POS. POS. Dead FF POS. NEG. Dead 34 AA NEG. Not tested Alive CC POS. Not tested Alive EE NEG. Not tested Alive II NEG. Not tested Alive KK NEG. Not tested Alive QQ NEG. Not tested Alive VV POS. Not tested Alive ZZ POS. Not tested Alive AAA POS. Not tested Alive S QQQ POS. Not tested Alive Marker transgenes such as MT-beta-Gal, and CMV-GFP were also transfected into blastodermal cells in vivo. Chicks were produced and tested for tissue expression of the transgene as described above. The transgenic DNA was detected in the following tissues which were tested: heart, liver, and kidney. These data indicate that the methods and constructs described herein are useful to transfect avian blastodermal cells and to make transgenic avian animals which produce a desired transgenic polypeptide. -16- WU UU//3UU "L 1/ UUU/4UUDY Example 8: Method for the production of tetrameric antibodies Unlike many prior art methods for production of transgenic chickens, the methods of the invention do not utilize retroviral particles. Many of those methods use non-replicating retroviruses, which contain a gene of interest, to infect a developing egg. This process has several limitations which include a restriction on the size of the gene packaged in the viral coat, and instability of expression from retroviral vectors. In addition, retroviral gene delivery is severely limited in its ability to produce high levels of multimeric proteins since each coding region would optimally require its own promoter. To circumvent this problem, some researchers have proposed the use of IRES sequences which allow for bicistronic mRNAs; however, the expression from these types of constructs is generally low unless a selection marker is used. To overcome these drawbacks, a technology was developed which employs in vitro gene delivery methods to the creation of transgenic chimeric chickens. This method has the advantage of being able to deliver a transgene of up to 100Kb and allows for high level production of multimeric proteins such as antibodies. The flexibility in vector design allows the construction of transgene similar to those used in the mammary gland expression system which employ full length promoters, genomic coding regions, and 3'flanking regions. The method described herein utilizes the full 8Kb ovalbumin promoter, genomic or cDNA coding regions, and 3'flanking sequence. In addition, high level production of multimeric proteins is made possible because expression of each subunit is directed by its own promoter. The transgenes are transfected individually or ligated together to ensure co-integration which greatly facilitates germline transmission of all subunits (Step 1 and 2 of Fig. 2). To ensure the equal expression of both subunits of the antibody, the transgene is insulated from the effects of the surrounding chromatin structure by including elements such as matrix attachment regions (Step 3 of Fig. 2). Unlike prior art methods which have utilized matrix attachment region, the constructs described herein result in equal expression of multimeric proteins. The elements are called A-elements, MAR for matrix attachment regions, SAR, scaffolding attachment regions, DCR for dominant control region, and insulators. Other features, objects, and advantages of the invention will be apparent from the description and from the claims. In the specification and the appended claims, the singular forms include plural references unless the context clearly dictates otherwise. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly -17- WU UU/753UU PC'/LSUU/4UU59 understood by one of ordinary skill in the art to which this invention belongs. All patents and publications cited in this specification are incorporated by reference. Other embodiments are within the following claims. -18-
Claims (25)
1. A method of introducing a nucleic acid molecule into the genome of an avian species, comprising contacting in vivo a blastodermal cell of a fertilized egg with said nucleic acid molecule, wherein said nucleic acid molecule is not associated with a viral coat protein 5 and wherein said nucleic acid molecule is introduced directly into the germinal disc of said egg in a volume of greater than 1 microliter and less than 0.5 milliliters.
2. The method of claim 1, wherein said volume is 5-100 microliters. 0
3. The method of claim 1, wherein said volume is 40-60 microliters.
4. The method of claim 1, wherein said volume is 10-20 microliters.
5. The method of claim 1, wherein said nucleic acid molecule is introduced into said 5 egg in a volume that is less than the volume of the germinal disc.
6. The method of claim 1, further comprising exposing said cell to an electrical current in vivo. 0
7. The method of claim 1, wherein said avian species is selected from the group consisting of a chickens, an ostrich, an emu, a turkeys, a duck, a goose, a quail a parrot, a parakeet, a cockatoo, and a cockatiel.
8. The method of claim 1, wherein said avian species is a chicken. 5
9. The method of claim 8, wherein the breed of said chicken is selected from the group consisting of White Leghorn, White Plymouth Rock, Barred Plymouth Rock, Rhode Island Red, New Hampshire and Dark Cornish. o
10. The method of claim 1, wherein said blastodermal cell is contacted with said nucleic acid during developmental stage X of said egg. -19-
11. The method of claim 1, wherein said blastodermal cell is contacted with said nucleic acid at a time after oviposition but before incubation of said egg.
12. The method of claim 1, wherein said nucleic acid comprises a sequence encoding an antibody or fragment thereof.
13. The method of claim 1, wherein said antibody or fragment thereof is human.
14. The method of claim 1, wherein said nucleic acid comprises a sequence encoding an insulin polypeptide, a growth hormone polypeptide, a calcitonin polypeptide, or a serum albumin polypeptide.
15. The method of claim 14, wherein said insulin polypeptide is a porcine single chain insulin polypeptide.
16. The method of claim 1, wherein said nucleic acid comprises a egg-specific transcriptional regulatory element.
17. The method of claim 16 wherein said regulatory element comprises a matrix attachment region of a chicken lysozyme gene.
18. The method of claim 17, wherein said region comprises a sequence from position 11.7 to -8.8 or from position +5.3 to +9.0 of the chicken lysozyme gene.
19. The method of claim 17, wherein said region is operably linked to a sequence encoding an antibody chain or fragment thereof
20. The method of claim 17, wherein said region is operably linked to a first sequence encoding an antibody light chain and a second sequence encoding an antibody heavy chain.
21. A transgenic avian animal, the genome of which comprises a nucleic acid sequence encoding a non-avian antibody polypeptide. -20-
22. The animal of claim 21, wherein said sequence encodes a human antibody polypeptide.
23. A transgenic avian animal, the genome of which comprises a nucleic acid sequence encoding a non-avian insulin polypeptide.
24. A transgenic avian animal, the genome of which comprises a nucleic acid encoding a non-avian polypeptide, wherein said polypeptide is selected from the group consisting of a calcitonin polypeptide, a growth hormone polypeptide, and a serum albumin polypeptide.
25. An isolated avian blastodermal cell comprising a transgene encoding an antibody, an insulin, a growth hormone, a serum albumin, or a calcitonin polypeptide. -21-
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13776199P | 1999-06-04 | 1999-06-04 | |
US60/137761 | 1999-06-04 | ||
PCT/US2000/040059 WO2000075300A2 (en) | 1999-06-04 | 2000-06-02 | Methods for manipulating the avian genome |
Publications (2)
Publication Number | Publication Date |
---|---|
AU5789800A true AU5789800A (en) | 2000-12-28 |
AU777420B2 AU777420B2 (en) | 2004-10-14 |
Family
ID=22478939
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU57898/00A Ceased AU777420B2 (en) | 1999-06-04 | 2000-06-02 | Methods for manipulating the avian genome |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1190042A2 (en) |
JP (1) | JP2003501083A (en) |
AU (1) | AU777420B2 (en) |
CA (1) | CA2375441A1 (en) |
NZ (1) | NZ516173A (en) |
WO (1) | WO2000075300A2 (en) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1468250A (en) | 2000-08-03 | 2004-01-14 | ��ķһ����˹��̹ | Production of humanized antibodies in transgenic animals |
US20020108132A1 (en) * | 2001-02-02 | 2002-08-08 | Avigenics Inc. | Production of a monoclonal antibody by a transgenic chicken |
MXPA04001333A (en) | 2001-08-13 | 2004-05-05 | Embrex Inc | Methods for injecting avian eggs. |
EP1438401B1 (en) * | 2001-09-18 | 2011-06-15 | Synageva BioPharma Corp. | Production of a transgenic avian by cytoplasmic injection |
AU2002341795A1 (en) * | 2001-09-21 | 2003-04-01 | Avigenics, Inc. | Production of transgenic avians using sperm-mediated transfection |
US7323618B2 (en) | 2002-02-01 | 2008-01-29 | Origen Therapeutics, Inc. | Tissue specific expression of exogenous proteins in transgenic chickens |
US7145057B2 (en) | 2002-02-01 | 2006-12-05 | Origen Therapeutics, Inc. | Chimeric bird from embryonic stem cells |
US20060191026A1 (en) | 2005-02-18 | 2006-08-24 | Origen Therapeutics, Inc. | Tissue specific expression of antibodies in chickens |
AU2003212958A1 (en) * | 2002-02-08 | 2003-09-02 | Tranxenogen, Inc. | Immunoglobulin purification |
US7585963B2 (en) * | 2003-04-15 | 2009-09-08 | Synageva Biopharma Corp. | Chicken ovalbumin nucleotide sequence |
WO2005007696A2 (en) | 2003-07-15 | 2005-01-27 | Therapeutic Human Polyclonals, Inc. | Humanized immunoglobulin loci |
CN102719444B (en) | 2006-09-01 | 2016-12-14 | 人类多细胞株治疗学公司 | The expression that people or Humanized immunoglobulin strengthen in non-human transgenic animal |
KR101720394B1 (en) | 2011-09-21 | 2017-03-27 | 후지레비오 가부시키가이샤 | Antibody against affinity complex |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5162215A (en) * | 1988-09-22 | 1992-11-10 | Amgen Inc. | Method of gene transfer into chickens and other avian species |
EP0424044A1 (en) * | 1989-10-16 | 1991-04-24 | Merck & Co. Inc. | Transgenic fowl expressing bovine growth hormone |
GB2282139A (en) * | 1993-09-24 | 1995-03-29 | Univ Reading | Introducing DNA into the germ line of birds |
EP0919121A4 (en) * | 1996-07-08 | 2000-11-22 | Dnavec Research Inc | In vivo electroporation method for early animal embryo |
CA2311116A1 (en) * | 1997-08-22 | 1999-03-04 | University Of Guelph | Production of proteins in eggs |
DE69842019D1 (en) * | 1997-10-16 | 2011-01-05 | Synageva Biopharma Corp | TRANSGENIC BIRDS AND PROTEIN PRODUCTION |
-
2000
- 2000-06-02 WO PCT/US2000/040059 patent/WO2000075300A2/en not_active Application Discontinuation
- 2000-06-02 JP JP2001502566A patent/JP2003501083A/en not_active Withdrawn
- 2000-06-02 AU AU57898/00A patent/AU777420B2/en not_active Ceased
- 2000-06-02 EP EP00943424A patent/EP1190042A2/en not_active Withdrawn
- 2000-06-02 NZ NZ516173A patent/NZ516173A/en unknown
- 2000-06-02 CA CA002375441A patent/CA2375441A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU777420B2 (en) | 2004-10-14 |
CA2375441A1 (en) | 2000-12-14 |
EP1190042A2 (en) | 2002-03-27 |
JP2003501083A (en) | 2003-01-14 |
WO2000075300A3 (en) | 2002-01-10 |
WO2000075300A2 (en) | 2000-12-14 |
NZ516173A (en) | 2004-02-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6377095B2 (en) | Vector containing a magnum-specific promoter for avian transgenes | |
US7378086B2 (en) | Retroviral vector having an ovalbumin promoter | |
AU777420B2 (en) | Methods for manipulating the avian genome | |
US20020150577A1 (en) | Use of antibodies specific for growth differentiation factor-11 | |
Houdebine | Transgenic animals | |
AU669484B2 (en) | Transgenic protein production | |
US20010053358A1 (en) | Growth differentiation factor-11 | |
JP2001501482A (en) | Production of recombinant peptides by transgenic fish | |
US20130131317A1 (en) | Expression of secreted human alpha-fetoprotein in transgenic animals | |
Shuman | Production of transgenic birds | |
CN101868144A (en) | Transgenic chickens with an inactivated endogenous gene locus | |
US5789651A (en) | Isolation and characterization of Agouti: a diabetes/obesity related gene | |
JP2006262875A (en) | Gene construct for expressing protein in poultry fallopian tube, and method for producing protein using the gene construct | |
US20040172666A1 (en) | Transgenic birds and method of producing protein using same | |
CN113226021A (en) | Genetically modified avian and methods of reconstituting same | |
US20100107265A1 (en) | Double-muscling in mammals | |
KR20220111143A (en) | Preparing method of transgenic germ cell and transgenic animal using the same | |
WO1994006903A9 (en) | Delivery of proteins by intermembrane transfer for preaccommodation of xenogeneic organ transplants and other purposes | |
Hull | Restriction Enzyme Mediated Integration and Lentiviral Transgenesis of the Species Eublepharis macularius, Litoria caerulea, and Xenopus laevis. | |
MXPA03001281A (en) | Use of a transgene encoding a vertebrate phytase to increase capacity to utilize phytic acid in livestock feed. | |
Velander et al. | TRANSGENIC NONHUMAN MAMMALS PRODUCING FIBRINOGEN IN MILKAND METHODS OF PRODUCING FIBRIN | |
AU1830201A (en) | Tissue specific synthesis of protein in eggs of transgenic hens |